Coronavirus in Russia: The Latest News | May 8 Updated:
cases of coronavirus and
112,922 deaths, according to the national coronavirus information center. Russia’s total excess fatality count since the start of the coronavirus pandemic is above 460,000.
May 8: What you need to know today
Russia on Saturday confirmed 8,329 new coronavirus cases and 370 deaths.
The makers of Russia’s third coronavirus vaccine CoviVak said their tests of a live polio vaccine for preventing Covid-19 have proven effective.
The makers of Russia’s second approved coronavirus vaccine EpiVacCorona are studying third doses to boost recipients immune response, a senior scientist said Wednesday.
April 30 Turkey s Medicines and Medical Devices Agency gave emergency authorization to Russia s Sputnik V coronavirus vaccine, the jab s developers confirmed Friday.
Friday, 07 May 2021 07:39 AM MYT
A person walks past the Pfizer Headquarters building in the Manhattan borough of New York November 9, 2020. Reuters pic
Subscribe to our Telegram channel for the latest updates on news you need to know.
WASHINGTON, May 7 A bold US bid to waive patents on much-needed coronavirus vaccines was strongly opposed by Germany on Thursday, threatening to derail the proposal that requires the consensus of World Trade Organization members to pass.
Pfizer CEO Albert Bourla meanwhile told AFP his company was “not at all” in favour of the measure, insisting intellectual property is not the main roadblock to more production and that building new plants would be counterproductive.
SHARE
Germany will allow AstraZeneca s Covid-19 vaccine to be given to adults of all ages, reversing a previous decision that restricted it to people over 60 years.
Germany is doing away with limiting AstraZeneca shots to priority groups and will instead make it available immediately to all over-18s, Health Minister Jens Spahn said.
He also said Germany aimed to offer those aged 12 to 18 a vaccine by the end of August, provided regulators give approval for the Pfizer/ BioNTech shot for that age group.
Read More
Millions of doses of the AstraZeneca vaccine have been safely administered in Europe, but concerns linger over a rare type of blood clot seen in an extremely small number of recipients, meaning that some people in early priority groups due to their age or pre-existing health conditions have been holding off on receiving it, preferring to wait for another vaccine.
The Latest: Pfizer aims for full FDA approval of vaccine
The Associated Press
FacebookTwitterEmail 17
1of17FILE - In this Dec. 14, 2020, file photo, a vial of the Pfizer vaccine for COVID-19 sits on a table at Hartford Hospital in Hartford, Conn. Many parents and educators are excited over the news that the Food and Drug Administration is expected to authorize Pfizer’s COVID-19 vaccine soon for youngsters ages 12 to 15.Jessica Hill/APShow MoreShow Less
2of17Seiko Hashimoto, president of the Tokyo 2020 Organizing Committee, speaks during a press conference Friday, May 7, 2021 in Tokyo, Japan. Hashimoto said Friday that a planned visit to Japan this month by IOC President Thomas Bach seemed unlikely with a state of emergency order being extended by the government to Tokyo and other areas until May 31.(Kyodo News via AP)APShow MoreShow Less
Updated / Friday, 7 May 2021
11:50
CVI advised that another vaccine should be offered to under-40s
UK regulators said under-40s are to be offered an alternative to the Oxford/AstraZeneca coronavirus vaccine.
The Joint Committee on Vaccination and Immunisation (JCVI) said there is an extremely small risk of people suffering blood clots after having the jab, but the risk of serious illness with Covid-19 also drops for younger people as infection rates fall across the country.
While the balance of benefit and risk for the AstraZeneca vaccine is very favourable for older people, it is more finely balanced for younger groups, who do not tend to suffer serious coronavirus illness.